Concord Biotech Limited (NSE:CONCORDBIO)
India
· Delayed Price · Currency is INR 1,650.20
-27.80 (-1.66%)
Feb 21, 2025, 3:30 PM IST
Concord Biotech Revenue
Concord Biotech had revenue of 2.44B INR in the quarter ending December 31, 2024, with 1.42% growth. This brings the company's revenue in the last twelve months to 10.89B, up 12.22% year-over-year. In the fiscal year ending March 31, 2024, Concord Biotech had annual revenue of 10.17B with 19.20% growth.
Revenue (ttm)
10.89B
Revenue Growth
+12.22%
P/S Ratio
15.85
Revenue / Employee
7.91M
Employees
1,377
Market Cap
172.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 10.17B | 1.64B | 19.20% |
| Mar 31, 2023 | 8.53B | 1.40B | 19.67% |
| Mar 31, 2022 | 7.13B | 959.91M | 15.56% |
| Mar 31, 2021 | 6.17B | 1.05B | 20.42% |
| Mar 31, 2020 | 5.12B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |